Finanzen von Lantern Pharma Inc (LTRN)LTRNLantern Pharma Inc

Evaluating the bottom line, Lantern Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -400.92%, provide a clear picture of how effectively LTRN converts its operational activities into shareholder value.

In the context of the broader market, LTRN competes directly with industry leaders such as ATOS and TXMD. With a market capitalization of $27.61M, it holds a leading position in the sector. When comparing efficiency, LTRN's gross margin of N/A stands against ATOS's N/A and TXMD's N/A. Such benchmarking helps identify whether Lantern Pharma Inc is trading at a premium or discount relative to its financial performance.

Lantern Pharma has been experiencing substantial losses, with a net income of -$7.1 million in Q2 2026 and a negative EPS of -0.57. The current ratio is also concerning at 1.96, indicating potential liquidity issues as it approaches the critical threshold of 1.